NGeneBio Co., Ltd.

As of June 30, 2026, NGeneBio Co., Ltd. carries a market capitalization of 19.76B, placing it among publicly traded companies globally. Its enterprise value stands at 49.14B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, NGeneBio Co., Ltd. has 10.62M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 0.45, and the price-to-book ratio stands at 1.03.

These figures are as of June 30, 2026. The EV/Sales ratio of 1.18 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 49.14B versus a market cap of 19.76B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, NGeneBio Co., Ltd. maintains a current ratio of 0.45, meaning it holds 0.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 194.73, indicating elevated leverage, while an interest coverage ratio of -1.33 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, NGeneBio Co., Ltd. posted a negative return on equity (ROE) of -27.27, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -9.92, reflecting losses generated across the asset base. The company generates approximately 633.39M in revenue per employee across its workforce of 66.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 26.01 indicates how many times NGeneBio Co., Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

As of the close on October 23, 2026, NGeneBio Co., Ltd.'s stock has declined approximately 82.55% over the past 52 weeks. The 50-day moving average sits at 1,357.18, while the 200-day moving average is 3,191.01.

Over the twelve months ended June 30, 2026, NGeneBio Co., Ltd. generated 41.80B in revenue and converted that into -5.06B in net income, yielding earnings per share of -478.02. EBITDA reached -4.86B, while operating income came in at -6.30B.

As of June 30, 2026, NGeneBio Co., Ltd. holds 6.55B in cash and equivalents against 36.39B in total debt, resulting in a net debt position of 33.00B. Total book value stands at 19.14B, with working capital of -28.02B providing operational flexibility.

NGeneBio Co., Ltd. produced -5.13B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -987.68M in capital expenditures, free cash flow totaled -6.11B - equivalent to -599.94 per share.

Over the twelve months ended June 30, 2026, NGeneBio Co., Ltd. posted a gross margin of 13.89, reflecting its pricing power and cost economics. The operating margin of -15.08 and net profit margin of -12.10 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -32.25: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -129.33, meaning NGeneBio Co., Ltd. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

NGeneBio Co., Ltd.'s most recent stock split took place on July 21, 2026 with a 69:82 split ratio.

As of June 30, 2026, NGeneBio Co., Ltd. has an Altman Z-Score of -1.27, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.